Peptide Drug Discovery Market

Peptide Drug Discovery Market Overview

The peptide drug discovery market is estimated to be worth $560 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 10.5% during the forecast period.Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles. In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are currently being evaluated in clinical trials, while over 500 molecules are still in the early stages of development.  

It has been reported that the overall process of drug development, from peptide discovery of a molecule to its commercial launch, takes around 10-15 years and involves capital investments worth USD 4-10 billion. However, only a small proportion of the molecules, which are selected for further investigation during the initial stages of research, actually enter the market. Given the complexities associated with the peptide drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, the discovery of peptides and macrocycles for therapeutic use is a long, arduous and cost intensive process. As a result, many developers are opting to outsource such operations to specialty CROs. In addition, there are multiple technology platform providers, which offer licenses to proprietary peptide discovery platforms that can be used by interested drug developers / manufacturers. We believe that, as the demand for peptide therapeutics increases, the opportunity for contract service provides and technology developers engaged in peptide drug discovery market is also likely to witness a substantial market growth during the forecast period.

Key Companies in Peptide Drug Discovery Market

Examples of key companies engaged in peptide drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include GenScript, JPT Peptide Technologies, CPC Scientific, IRBM, Creative Peptides, Pepscan, Interprotein, RA Pharmaceuticals, Pepticom, PeptiDream, Creative Biolabs and MeSCue-Janusys. This market report includes an easily searchable excel database of all the companies providing peptide drug discovery platforms and services, worldwide.

Recent Developments in Peptide Drug Discovery Market:

Several recent developments have taken place in the field of peptide drug discovery market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Parabilis Medicines entered into a collaboration with Regeneron Pharmaceuticals to develop peptide-based Antibody-Helicon conjugates targeting difficult intracellular proteins.
• In March 2026, Pinnacle Medicines raised $89 million in Series B financing round bringing total funding to $134 million. The proceeds will advance its AI-driven oral peptide therapeutics pipeline into clinical trials, supporting proof-of-concept studies and expanding peptide drug discovery capabilities across multiple disease areas.
• In March 2026, Decoy Therapeutics entered into a collaboration with Quantori, supported by Google Cloud funding, to deploy a cloud-native AI-driven peptide design and molecular simulation platform. The collaboration aims to increase computational peptide discovery capacity by 25–100x, accelerating antiviral peptide development and enabling scalable, high-throughput drug discovery workflows in infectious disease research.
• In February 2026, Novo Nordisk collaborated with Vivtex in order to develop next-generation oral peptide and protein therapeutics for obesity and diabetes.
• In February 2026, Unnatural Products entered into a licensing and research agreement with Novartis in order to develop macrocyclic peptide therapeutics targeting cardiovascular diseases. The deal leverages AI-enhanced peptide platforms and includes significant milestone-based economics, with Novartis responsible for clinical development and commercialization of candidates addressing historically undruggable targets.

Scope of the Report

The “Peptide Drug Discovery Market, 2020-2030” market report features an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the peptide drug discovery market. The market research report includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the market research report includes:

• A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services, including developer information (year of establishment, company size and location of headquarters), type of peptide manufactured (linear, cyclic, helical and others), drug discovery steps covered in service portfolio (target validation, hit identification, lead generation and lead optimization), peptide generation methods used (liquid phase synthesis, solid phase synthesis, microwave-assisted synthesis, recombinant methods and others), peptide modification services (C-terminal, N-terminal, fret / quenching tags, immunogenic conjugates, linkers / spacers, unnatural AAS, cyclization, stable isotope labels and post-translational modification services) and other services offered (peptide isolation / purification service, peptide detection / identification service and peptide quantification service).
• An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size). 
• An in-depth analysis of peptide platform and library service providers, featuring information on their company details (year of establishment, company size and location of headquarters), purpose of the platform, type of peptide manufactured (linear, cyclic, helical and others) and platform access model (pipeline licensing, technology licensing, strategic alliance and library provider).
• Profiles of peptides and macrocycle drug discovery service providers, featuring information on the year of establishment, location of headquarters, peptide discovery service / platform portfolio, recent developments and an informed future outlook.
• An analysis of the partnerships that have been established in the recent past, covering R&D agreements, licensing agreements, acquisitions and other form of collaborations.

The key objective of peptide drug discovery market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for peptide drug discovery market during the forecast period. Based on multiple parameters, such as R&D spend, we have developed an informed estimate on the financial evolution of the market over the forecast period, 2020-2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] different type of product (synthetic peptides, biological and recombinant peptides and macrocycles), [B]  drug discovery steps (target identification and validation, hit identification, lead generation and lead optimization), [C] therapeutic area (oncological disorders, metabolic disorders, cardiovascular disorders, infectious disorders, urological disorders, endocrine disorders, CNS disorders, and other diseases), [D] company size (small, mid-sized and large and very large companies) and [E] geography (North America, Europe, Asia Pacific). To account for the uncertainties associated with the drug discovery services and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interview(s) held with the following industry stakeholders:

• Chief Operating Officer, Cyclenium Pharma
• Anonymous

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is peptide drug discovery?

Answer: Peptide drug discovery refers to the process of identifying potential therapeutic peptides followed by biological or synthetic modifications to enhance its pharmacological effectiveness.

Question 2: How big is the peptide drug discovery market?

Answer: The peptide drug discovery market size is estimated to be worth $560 million in 2020.

Question 3: What is the projected market growth of the peptide drug discovery market?

Answer: The peptide drug discovery market is expected to grow at compounded annual growth rate (CAGR) of 10.5% during the forecast period 2020 – 2030.

Question 4: Who are the leading players in the peptide drug discovery market?

Answer: Examples of key companies engaged in peptide drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include GenScript, JPT Peptide Technologies, CPC Scientific, IRBM, Creative Peptides, Pepscan, Interprotein, RA Pharmaceuticals, Pepticom, PeptiDream, Creative Biolabs and MeSCue-Janusys.

Question 5: How many companies are currently offering peptide drug discovery services?

Answer: Over 35 companies are currently offering peptide drug discovery services.

Question 6: How many companies are currently offering peptide drug discovery platforms?

Answer: Over 20 companies are currently offering peptide drug discovery platforms.

Question 7: How many partnership deals have been inked between the companies engaged in peptide drug discovery market?

Answer: More than 55 partnership deals have been inked between the players engaged in peptide drug discovery market, highlighting the consolidation efforts of stakeholders in the industry.